Innovative Health Initiative (IHI)

The Innovative Health Initiative is the new Horizon Europe Partnership in the area of health.

The Innovative Health Initiative (IHI) aims to:

  • create an EU-wide health research and innovation ecosystem that facilitates translation of scientific knowledge into innovations;
  • foster the development of safe, effective, people-centred and cost-effective innovations that respond to strategic unmet public health needs currently insufficiently served by industry;
  • drive cross-sectoral health innovation for a globally competitive European health industry.

It will cover prevention, diagnostics, treatment and disease management.

IHI will contribute to a number of European policies. This includes:  Europe’s Beating Cancer Plan, the new Industrial Strategy for Europe and the Pharmaceutical Strategy for Europe.

The budget proposed for IHI is 2.4 billion euros.

An online launch event to ‘Introduce the Innovative Health Initiative: Europe’s new partnership for health‘ will take place on 26 January 2022.

Strategic Research and Innovation Agenda

The new IHI partnership is currently under development. IHI draft Strategic Research and Innovation Agenda (SRIA) can now be consulted online.

The SRIA will guide the direction of the partnership under Horizon Europe in the coming years.

Public-Private Partnership

This newly proposed Joint Undertaking under Horizon Europe will have:

IMI Successor

IHI will build on the experience, lessons learnt and successes of two H2020 joint undertakings:

  • Innovative Medicine Initiative 2 (IMI2), partnership between the EU and the European pharmaceutical industry;
  • Electronic Components and Systems for European Leadership (health activities of ECSEL).

Cross-sectorial collaboration in health research & innovation

Like IMI, IHI will bring together a range of stakeholders in collaborative projects. However,  IHI will:

  • have a greater focus on cross-sectoral collaboration;
  • include all stakeholders in the patient’s journey (e.g. the biopharmaceutical, biotechnology and medical technology sectors).